4-[1-(4-Fluorobenzyl)-4-hydroxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid as a prototype to develop dual inhibitors of HIV-1 integration process

Antiviral Research

Volumn 92, Issue 1, 2011, Pages 102-107

  De Luca, Laura ^a   Gitto, Rosaria ^a   Christ, Frauke ^b   Ferro, Stefania ^a   De Grazia, Sara ^a   Morreale, Francesca ^a   Debyser, Zeger ^b   Chimirri, Alba ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Dual inhibitor; HIV 1 integrase; IN LEDGF p75; INSTI

Indexed keywords

4 [1(3,5 DIMETHYLBENZYL) 4 HYDROXY 1H INDOL 3 YL] 2 HYDROXY 4 OXOBUT 2 ENOIC ACID; 4 [1(3,5 DIMETHYLBENZYL) 4 METHOXY 1H INDOL 3 YL] 2 HYDROXY 4 OXOBUT 2 ENOIC ACID; 4 [1(4 FLUOROBENZYL) 4 HYDROXY 1H INDOL 3 YL] 2 HYDROXY 4 OXOBUT 2 ENOIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHI 1043; INTEGRASE; LENS EPITHELIUM DERIVED GROWTH FACTOR; PROTEIN P75; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOPATHOGENIC EFFECT; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN INTERACTION; VIRUS DNA CELL DNA INTERACTION;

CELL LINE; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; HYDROXYBUTYRATES; INDOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR CONFORMATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; VIRUS INTEGRATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80052862237     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.07.005     Document Type: Article

References (38)

1. Al-Mawsawi L.Q., Neamati N. Allosteric inhibitor development targeting HIV-1 Integrase. Chem. Med. Chem. 2011, 6:228-241.
2. Barbaro G., Scozzafava A., Mastrolorenzo A., Supuran C.T. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr. Pharm. Des. 2005, 11:1805-1843.
3. Barreca M.L., Ferro S., Rao A., De Luca L., Zappala M., Monforte A.M., Debyser Z., Witvrouw M., Chimirri A. Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors. J. Med. Chem. 2005, 48:7084-7088.
4. Benkhelifa-Ziyyat S., Bucher S., Zanta-Boussif M.A., Pasquet J., Danos O. Changes in the accessibility of the HIV-1 Integrase C-terminus in the presence of cellular proteins. Retrovirology 2010, 7:27.
5. Busschots K., Voet A., De Maeyer M., Rain J.C., Emiliani S., Benarous R., Desender L., Debyser Z., Christ F. Identification of the LEDGF/p75 binding site in HIV-1 integrase. J. Mol. Biol. 2007, 365:1480-1492.
6. Cherepanov P., Ambrosio A.L., Rahman S., Ellenberger T., Engelman A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc. Natl. Acad. Sci. USA 2005, 102:17308-17313.
7. Christ F., Voet A., Marchand A., Nicolet S., Desimmie B.A., Marchand D., Bardiot D., Van der Veken N.J., Van Remoortel B., Strelkov S.V., De Maeyer M., Chaltin P., Debyser Z. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat. Chem. Biol. 2010, 6:442-448.
8. De Clercq E. Strategies in the design of antiviral drugs. Nat. Rev. Drug. Discov. 2002, 1:13-25.
9. De Clercq E. New approaches toward anti-HIV chemotherapy. J. Med. Chem. 2005, 48:1297-1313.
10. De Luca L., Barreca M.L., Ferro S., Iraci N., Michiels M., Christ F., Debyser Z., Witvrouw M., Chimirri A. A refined pharmacophore model for HIV-1 integrase inhibitors: optimization of potency in the 1H-benzylindole series. Bioorg. Med. Chem. Lett. 2008, 18:2891-2895.
11. De Luca L., Barreca M.L., Ferro S., Christ F., Iraci N., Gitto R., Monforte A.M., Debyser Z., Chimirri A. Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. Chem. Med. Chem. 2009, 4:1311-1316.
12. De Luca L., Ferro S., Gitto R., Barreca M.L., Agnello S., Christ F., Debyser Z., Chimirri A. Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor. Bioorg. Med. Chem. 2010, 18:7515-7521.
13. De Luca L., De Grazia S., Ferro S., Gitto R., Christ F., Debyser Z., Chimirri A. HIV-1 integrase strand-transfer inhibitors: design, synthesis and molecular modeling investigation. Eur. J. Med. Chem. 2011, 46:756-764.
14. DeLano, W.L., DeLano Scientific LLC, The PyMOL Molecular Graphics System, San Carlos, CA, USA, 2008 http://www.pymol.org.
15. Dyda F., Hickman A.B., Jenkins T.M., Engelman A., Craigie R., Davies D.R. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994, 266:1981-1986.
16. Faure A., Calmels C., Desjobert C., Castroviejo M., Caumont-Sarcos A., Tarrago-Litvak L., Litvak S., Parissi V. HIV-1 integrase crosslinked oligomers are active in vitro. Nucleic Acids Res. 2005, 33:977-986.
17. Ferro S., Rao A., Zappala M., Chimirri A., Barreca M.L., Witvrouw M., Debyser Z., Monforte P. Synthesis of new potential HIV-1 integrase inhibitors. Heterocycles 2004, 2727:27234.
18. Ferro S., Barreca M.L., De Luca L., Rao A., Monforte A.M., Debyser Z., Witvrouw M., Chimirri A. New 4-[(1-benzyl-1H-indol-3-yl)carbonyl]-3-hydroxyfuran-2(5H)-ones, beta-diketo acid analogs as HIV-1 integrase inhibitors. Arch. Pharm. (Weinheim) 2007, 340:292-298.
19. Ferro, S., Barreca, M.L., De Luca, L., Rao, A., Monforte, A.M., Michiels, M., Witvrouw, M., Debyser, Z., Chimirri, A., 2007. HIV-1 Integrase strand transfer inhibitors (INSTIS): design, synthesis and biological evaluation. Reports from the 5th Joint Meeting on Medicinal Chemistry, Portoroz (Slovenia) June 16-21, 2007, Medimond International Proceedings, 11-15.
20. Ferro S., De Grazia S., De Luca L., Barreca M.L., Debyser Z., Chimirri A. Structural modification of diketo acid portion in 1H-benzylindole derivatives HIV-1 integrase inhibitors. Heterocycles 2009, 78:947-959.
21. Ferro S., De Luca L., Barreca M.L., Iraci N., De Grazia S., Christ F., Witvrouw M., Debyser Z., Chimirri A. Docking studies on a new human immunodeficiency virus integrase-Mg-DNA complex: phenyl ring exploration and synthesis of 1H-benzylindole derivatives through fluorine substitutions. J. Med. Chem. 2009, 52:569-573.
22. Ferro S., De Luca L., Barreca M.L., De Grazia S., Christ F., Debyser Z., Chimirri A. New chloro, fluorobenzylindole derivatives as integrase strand-transfer inhibitors (INSTIs) and their mode of action. Bioorg. Med. Chem. 2010, 18:5510-5518.
23. Greene W.C., Debyser Z., Ikeda Y., Freed E.O., Stephens E., Yonemoto W., Buckheit R.W., Esté J.A., Cihlar T. Novel targets for HIV therapy. Antiviral Res. 2008, 80:251-265.
24. Guiot E., Carayon K., Delelis O., Simon F., Tauc P., Zubin E., Gottikh M., Mouscadet J.F., Brochon J.C., Deprez E. Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity. J. Biol. Chem. 2006, 281:22707-22719.
25. Hare S., Gupta S.S., Valkov E., Engelman A., Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010, 464:232-236.
26. Hare S., Vos A.M., Clayton R.F., Thuring J.W., Cummings M.D., Cherepanov P. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc. Natl. Acad. Sci. USA 2010, 107:20057-20062.
27. Hombrouck A., Van Remoortel B., Michiels M., Noppe W., Christ F., Eneroth A., Sahlberg B.L., Benkestock K., Vrang L., Johansson N.G., Barreca M.L., De Luca L., Ferro S., Chimirri A., Debyser Z., Witvrouw M. Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors. Antimicrob. Agents Chemother. 2008, 52:2861-2869.
28. Jones G., Willett P., Glen R.C., Leach A.R., Taylor R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267:727-748.
29. McColl D.J., Chen X. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res. 2010, 85:101-118.
30. Nair V., Chi G., Ptak R., Neamati N. HIV integrase inhibitors with nucleobase scaffolds: discovery of a highly potent anti-HIV agent. J. Med. Chem. 2006, 49:445-447.
31. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988, 20:309-321.
32. Pommier Y., Marchand C., Neamati N. Retroviral integrase inhibitors year 2000: update and perspectives. Antiviral Res. 2000, 47:139-148.
33. Ramkumar K., Serrao E., Odde S., Neamati N. HIV-1 integrase inhibitors: 2007-2008 update. Med. Res. Rev. 2010, 30:890-954.
34. Sechi M., Carta F., Sannia L., Dallocchio R., Dessi A., Al-Safi R.I., Neamati N. Design, synthesis, molecular modeling, and anti-HIV-1 integrase activity of a series of photoactivatable diketo acid-containing inhibitors as affinity probes. Antiviral Res. 2009, 81:267-276.
35. Summa V., Petrocchi A., Bonelli F., Crescenzi B., Donghi M., Ferrara M., Fiore F., Gardelli C., Gonzalez Paz O., Hazuda D.J., Jones P., Kinzel O., Laufer R., Monteagudo E., Muraglia E., Nizi E., Orvieto F., Pace P., Pescatore G., Scarpelli R., Stillmock K., Witmer M.V., Rowley M. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 2008, 51:5843-5855.
36. Tintori C., Veljkovic N., Veljkovic V., Botta M. Computational studies of the interaction between the HIV-1 integrase tetramer and the cofactor LEDGF/p75: Insights from molecular dynamics simulations and the Informational spectrum method. Proteins 2010, 78:3396-3408.
37. Van Maele B., Busschots K., Vandekerckhove L., Christ F., Debyser Z. Cellular co-factors of HIV-1 integration. Trends Biochem. Sci. 2006, 31:98-105.
38. Wallace A.C., Laskowski R.A., Thornton J.M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995, 8:127-134.